VS-041 is currently being evaluated in a phase 1c trial in adult patients with heart failure with preserved ejection fraction and elevated serum levels of endotrophin. The Food and Drug Administration ...
TAIPEI, Jan. 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approval at its 2025 Extraordinary General Shareholders' Meeting, that Foresee ...
Preclinical findings have shown matrix metalloproteinase 7 (MMP-7) inhibition confers antifibrotic effects and thus, is a promising therapeutic strategy to treat idiopathic pulmonary fibrosis (IPF).
Zincure Corp. has discovered matrix metalloproteinase-9 (MMP-9, gelatinase B) inhibitors reported to be useful for the treatment of epilepsy, stroke, multiple sclerosis, hypoglycemic encephalopathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results